52-week Open Label Safety-Tolerability Study
Trial details
- Registry ID
- NCT07369154
- Drugs studied
- LB-102
TrialRedline tracks 4 clinical trials sponsored by LB Pharmaceuticals Inc.: 2 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| 52-week Open Label Safety-Tolerability StudyNCT07369154 | LB-102 | Recruiting | 2028-12Estimated |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaNCT07363577 | LB-102 (100 mg tablet), LB-102 (50 mg tablet) | Recruiting | 2027-06Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305 | LB-102 | Recruiting | 2028-02Estimated |
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 | LB-102 | Completed | 2024-12-04Actual |
Names as written in the registry records.
NCT07369154 · LB Pharmaceuticals Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07363577 · LB Pharmaceuticals Inc.
Before: Not yet recruiting. After: Recruiting.